WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from two Phase 2 proof-of-concept (POC) studies that investigated treatment with the ...
BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, ...
New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results